Anti-inflammatory modulation of microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA Parkinson’s disease model

Journal of Neuroscience

Volumn 36, Issue 36, 2016, Pages 9375-9390

  Tentillier, Noemie ^a   Etzerodt, Anders ^a   Olesen, Mads N ^a   Rizalar, F Sila ^a,c   Jacobsen, Jan ^a   Bender, Dirk ^a   Moestrup, Søren K ^a,b   Romero Ramos, Marina ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c KOÇ UNIVERSITY   (Turkey)

Author keywords

CD163; Dexamethasone; Dopamine; Macrophages; Microglia; Parkinson s disease

Indexed keywords

CD163 ANTIGEN; DEXAMETHASONE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; GLUCOCORTICOID; HYDROCORTISONE; LEUKOCYTE ANTIGEN; LIPOSOME; NERVE PROTEIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL ISOLATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD; CORPUS STRIATUM; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; LOCOMOTION; MACROPHAGE; METABOLISM; MICROGLIA; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FEMALE; GLUCOCORTICOIDS; HYDROCORTISONE; LIPOSOMES; LOCOMOTION; MACROPHAGES; MICROGLIA; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; TYROSINE 3-MONOOXYGENASE;

EID: 84986915900     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1636-16.2016     Document Type: Article

References (89)

1. Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133–141. CrossRef Medline
2. Banati RB, Daniel SE, Blunt SB (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov Disord 13:221–227. CrossRef Medline
3. Ben Rhouma K, Sakly M (1994) Involution of rat thymus: characterization of cytoplasmic glucocorticoid receptors, evidence of glucocorticoid resistant dexamethasone receptor-positive cells. Arch Int Physiol Biochim Biophys 102:97–102. Medline
4. Biju K, Zhou Q, Li G, Imam SZ, Roberts JL, Morgan WW, Clark RA, Li S (2010) Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson’s disease. Mol Ther 18:1536–1544. CrossRef Medline
5. Blandini F (2013) Neural and immune mechanisms in the pathogenesis of Parkinson’s disease. J Neuroimmune Pharmacol 8:189–201. CrossRef Medline
6. Borda JT, Alvarez X, Mohan M, Hasegawa A, Bernardino A, Jean S, Aye P, Lackner AA (2008) CD163, a marker of perivascular macrophages, is up-regulated by microglia in simian immunodeficiency virus encephalitis after haptoglobin-hemoglobin complex stimulation and is suggestive of breakdown of the blood-brain barrier. Am J Pathol 172:725–737. CrossRef Medline
7. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fisher D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182–192. CrossRef Medline
8. Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, Klyachko NL, Kabanov AV, Gendelman HE, Batrakova EV (2010) Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson’s disease. Nanomedicine (Lond) 5:379–396. CrossRef Medline
9. Castaño A, Herrera AJ, Cano J, Machado A (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 81:150–157. CrossRef Medline
10. Cebrián C, Loike JD, Sulzer D (2015) Neuroinflammation in Parkinson’s disease animal models: a cell stress response or a step in neurodegeneration? Curr Top Behav Neurosci 22:237–270. CrossRef Medline
11. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive6-OHDAdopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991–998. CrossRef Medline
12. Clerc S, Barenholz Y (1995) Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta 1240:257–265. CrossRef Medline
13. Cole MA, Kim PJ, Kalman BA, Spencer RL (2000) Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology 25: 151–167. CrossRef Medline
14. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2:14. CrossRef Medline
15. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH (2010) Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 13:195–201. CrossRef Medline
16. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, Lourhmati A, Klopfer T, Schaumann F, Schmid B, Koehle C, Proksch B, Weissert R, Reichardt HM, van den Brandt J, Buniatian GH, Schwab M, Gleiter CH, Frey WH 2nd (2011) Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 14:3–16. CrossRef Medline
17. Danielyan L, Beer-Hammer S, Stolzing A, Schäfer R, Siegel G, Fabian C, Kahle P, Biedermann T, Lourhmati A, Buadze M, Novakovic A, Proksch B, Gleiter CH, Frey WH, Schwab M (2014) Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant 23:S123–S139 Medline
18. Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Höglinger GU (2012) Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol 238:183–191. CrossRef Medline
19. Doorn KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, Drukarch B, van Dam AM (2012) Emerging roles of microglial activation and nonmotor symptoms in Parkinson’s disease. Prog Neurobiol 98:222–238. CrossRef Medline
20. Dultz G, Gerber L, Zeuzem S, Sarrazin C, Waidmann O (2016) The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitisCvirus infected patients. J Viral Hepat 23:267–273. CrossRef Medline
21. Etzerodt A, Moestrup SK (2013) CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 18:2352–2363. CrossRef Medline
22. Etzerodt A, Maniecki MB, Graversen JH, Møller HJ, Torchilin VP, Moestrup SK (2012a) Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release 160:72–80. CrossRef Medline
23. Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M (2013) Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson’s model. Exp Neurol 247:45–58. CrossRef Medline
24. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS (2011) Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect 119:807–814. CrossRef Medline
25. Garcia-Esparcia P, Llorens F, Carmona M, Ferrer I (2014) Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson’s disease brain is region dependent. Brain Pathol 24:584–598. CrossRef Medline
26. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. San Diego: Academic.
27. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412. CrossRef Medline
28. Graversen JH, Svendsen P, Dagnæs-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, Møller HJ, Moestrup SK (2012a) Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther 20:1550–1558. CrossRef Medline
29. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42:781–785. CrossRef Medline
30. Haney MJ, Zhao Y, Harrison EB, Mahajan V, Ahmed S, He Z, Suresh P, Hingtgen SD, Klyachko NL, Mosley RL, Gendelman HE, Kabanov AV, Batrakova EV (2013) Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PLoS One 8:e61852. CrossRef Medline
31. Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG (2013) MHCII is required for alphasynuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33:9592–9600. CrossRef Medline
32. Herrera AJ, Tomás-Camardiel M, Venero JL, Cano J, Machado A (2005) Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J Neural Transm 112:111–119. CrossRef Medline
33. Holfelder K, Schittenhelm J, Trautmann K, Haybaeck J, Meyermann R, Beschorner R (2011) De novo expression of the hemoglobin scavenger receptor CD163 by activated microglia is not associated with hemorrhages in human brain lesions. Histol Histopathol 26:1007–1017. Medline
34. Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72:355–363. CrossRef Medline
35. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class IIpositive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106:518–526. CrossRef Medline
36. Joers V, Tansey MG, Mulas G, Carta AR (2016) Microglial phenotypes in Parkinson’s disease and animal models of the disease. Prog Neurobiol. In press.
37. Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2. Mol Cell Neurosci 16:724–739. CrossRef Medline
38. Kokovay E, Cunningham LA (2005) Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson’s disease. Neurobiol Dis 19:471–478. CrossRef Medline
39. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O (2008) Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation 5:8. CrossRef Medline
40. Kowal K, Silver R, Sławińska E, Bielecki M, Chyczewski L, Kowal-Bielecka O (2011) CD163 and its role in inflammation. Folia Histochem Cytobiol 49:365–374. CrossRef Medline
41. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature 409:198–201. CrossRef Medline
42. Kurkowska-Jastrzebska I, Wrońska A, Kohutnicka M, Członkowski A, Członkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50–61. CrossRef Medline
43. Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybyłkowski A, Członkowski A, Członkowska A (2004) Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson’s disease. Int Immunopharmacol 4:1307–1318. CrossRef Medline
44. Liu B, Hu B, Shao S, Wu W, Fan L, Bai G, Shang P, Wang X (2015) CD163/ hemoglobin oxygenase-1 pathway regulates inflammation in hematoma surrounding tissues after intracerebral hemorrhage. J Stroke Cerebrovasc Dis 24:2800–2809. CrossRef Medline
45. Liu XY, Shi JH, Du WH, Fan YP, Hu XL, Zhang CC, Xu HB, Miao YJ, Zhou HY, Xiang P, Chen FL (2011) Glucocorticoids decrease body weight and food intake and inhibit appetite regulatory peptide expression in the hypothalamus of rats. Exp Ther Med 2:977–984. Medline
46. Lossinsky AS, Shivers RR (2004) Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol Histopathol 19:535–564. Medline
47. Madsen L, Labrecque N, Engberg J, Dierich A, Svejgaard A, Benoist C, Mathis D, Fugger L (1999) Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A 96:10338–10343. CrossRef Medline
48. Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD, Dexter DT (2009) Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease. J Neurochem 110: 966–975. CrossRef Medline
49. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci 26:9365–9375. CrossRef Medline
50. McCoy MK, Ruhn KA, Blesch A, Tansey MG (2011) TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson’s disease. Adv Exp Med Biol 691:539–540. CrossRef Medline
51. Miro-Mur F, Perez-de-Puig I, Ferrer-Ferrer M, Urra X, Justicia C, Chamorro A, Planas AM (2016) Immature monocytes recruited to the ischemic mouse brain differentiate into macrophages with features of alternative activation. Brain Behav Immun 53:18–33. CrossRef Medline
52. Moehle MS, West AB (2015) M1 and M2 immune activation in Parkinson’s disease: foe and ally? Neuroscience 302:59–73. CrossRef Medline
53. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208–210. CrossRef Medline
54. Mougin-Degraef M, Jestin E, Bruel D, Remaud-Le Saëc P, Morandeau L, Faivre-Chauvet A, Barbet J (2006) High-activity radio-iodine labeling of conventional and stealth liposomes. J Liposome Res 16:91–102. CrossRef Medline
55. Na SJ, DiLella AG, Lis EV, Jones K, Levine DM, Stone DJ, Hess JF (2010) Molecular profiling of a 6-hydroxydopamine model of Parkinson’s disease. Neurochem Res 35:761–772. CrossRef Medline
56. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 11:999–1016. CrossRef Medline
57. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649. CrossRef Medline
58. Nash KR, Moran P, Finneran DJ, Hudson C, Robinson J, Morgan D, Bickford PC (2015) Fractalkine over expression suppresses alpha-synucleinmediated neurodegeneration. Mol Ther 23:17–23. CrossRef Medline
59. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Tori zuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175. CrossRef Medline
60. Pey P, Pearce RK, Kalaitzakis ME, Griffin WS, Gentleman SM (2014) Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease. Acta Neuropathol Commun 2:21. CrossRef Medline
61. Polfliet MM, Fabriek BO, Daniëls WP, Dijkstra CD, van den Berg TK (2006) The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. Immunobiology 211: 419–425. CrossRef Medline
62. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ (2008) Central and systemic IL-1 exacerbatesneurodegenerationandmotorsymptomsinamodelof Parkinson’s disease. Brain 131:1880–1894. CrossRef Medline
63. Quan L, Zhang Y, Crielaard BJ, Dusad A, Lele SM, Rijcken CJ, Metselaar JM, Kostkova H, Etrych T, Ulbrich K, Kiessling F, Mikuls TR, Hennink WE, Storm G, Lammers T, Wang D (2014) Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano 8:458–466. CrossRef Medline
64. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. Cochrane Database Syst Rev 11:CD008454. CrossRef Medline
65. Rodriguez M, Alvarez-Erviti L, Blesa FJ, Rodríguez-Oroz MC, Arina A, Melero I, Ramos LI, Obeso JA (2007) Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson’s disease. Neurobiol Dis 28:316–325. CrossRef Medline
66. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS One 5:e8784. CrossRef Medline
67. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M (2013a) Neuroimmunological processes in Parkinson’s disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5:113–139. CrossRef Medline
68. Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M (2013b) alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol 72: 624–645. CrossRef Medline
69. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777–787. CrossRef Medline
70. Schlachetzki JC, Marxreiter F, Regensburger M, Kulinich A, Winner B, Winkler J (2014) Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson’s disease. Restor Neurol Neurosci 32: 447–462. CrossRef Medline
71. Simard AR, Rivest S (2004) Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J 18:998–1000. Medline
72. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrowderived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 49:489–502. CrossRef Medline
73. Stott SR, Barker RA (2014) Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson’s disease. Eur J Neurosci 39:1042–1056. CrossRef Medline
74. Tanaka S, Ishii A, Ohtaki H, Shioda S, Yoshida T, Numazawa S (2013) Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation 10: 143. CrossRef Medline
75. Theodore S, Maragos W (2015) 6-Hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson’s disease. Immunopharmacol Immunotoxicol 37:393–399. CrossRef Medline
76. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR (2001) p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 1511:397–411. CrossRef Medline
77. Van Gorp H, Delputte PL, Nauwynck HJ (2010) Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 47:1650–1660. CrossRef Medline
78. Villarán RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Argüelles S, Delgado-Cortés MJ, Sobrino V, Van Rooijen N, Venero JL, Herrera AJ, Cano J, Machado A (2010) Ulcerative colitis exacerbates LPS-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson’disease. J Neurochem 114:1687–1700. CrossRef Medline
79. Virgone-Carlotta A, Uhlrich J, Akram MN, Ressnikoff D, Chrétien F, Domenget C, Gherardi R, Despars G, Jurdic P, Honnorat J, Nataf S, Touret M (2013) Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson’s disease. Glia 61:1645–1658. CrossRef Medline
80. Walsh S, Finn DP, Dowd E (2011) Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson’s disease in the rat. Neuroscience 175:251–261. CrossRef Medline
81. Wattananit S, Tornero D, Graubardt N, Memanishvili T, Monni E, Tatarishvili J, Miskinyte G, Ge R, Ahlenius H, Lindvall O, Schwartz M, Kokaia Z (2016) Monocyte-derived macrophages contribute to spontaneous longterm functional recovery after stroke in mice. J Neurosci 36:4182–4195. CrossRef Medline
82. Westermeyer J (1991) Problems with managed psychiatric care without a psychiatrist-manager. Hosp Community Psychiatry 42:1221–1224. Medline
83. Wheeler CJ, Seksenyan A, Koronyo Y, Rentsendorj A, Sarayba D, Wu H, Gragg A, Siegel E, Thomas D, Espinosa A, Thompson K, Black K, Koronyo-Hamaoui M, Pechnick R, Irvin DK (2014) T-lymphocyte deficiency exacerbates behavioral deficits in the 6-OHDA unilateral lesion rat model for Parkinson’s disease. J Neurol Neurophysiol 5:pii:209. CrossRef Medline
84. Wissemann WT, Hill-Burns EM, Zabetian CP, Factor SA, Patsopoulos N, Hoglund B, Holcomb C, Donahue RJ, Thomson G, Erlich H, Payami H (2013) Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet 93:984–993. CrossRef Medline
85. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763–1771. Medline
86. Zhang Z, Zhang ZY, Schittenhelm J, Wu Y, Meyermann R, Schluesener HJ (2011) Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J Neuroimmunol 237:73–79. CrossRef Medline
87. Zhang Z, Zhang ZY, Wu Y, Schluesener HJ (2012) Lesional accumulation of CD163_macrophages/microglia in rat traumatic brain injury. Brain Res 1461:102–110. CrossRef Medline
88. Zhao Y, Haney MJ, Mahajan V, Reiner BC, Dunaevsky A, Mosley RL, Kabanov AV, Gendelman HE, Batrakova EV (2011) Active targeted macrophage-mediated delivery of catalase to affected brain regions in models of Parkinson’s disease. J Nanomed Nanotechnol S4:pii:003. CrossRef Medline
89. Zhao Y, Haney MJ, Gupta R, Bohnsack JP, He Z, Kabanov AV, Batrakova EV (2014) GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson’s disease mouse model. PLoS One 9:e106867. CrossRef Medline